Skip to main content

Table 3 Grade 3 or 4 Adverse Events (National Cancer Institute Common Toxicity Criteria, Version 3.0)

From: A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

 

Number (n = 61)

Percentage (%)

Hematological toxicity

 Neutropenia

32

52.5

 Febrile neutropenia

8

13.1

 Anemia

18

29.5

 Thrombocytopenia

5

8.2

Non-hematological toxicity

 Nausea

5

8.2

 Vomiting

4

6.6

 Stomatitis

1

1.6

 Diarrhea

4

6.6

 Infection

3

4.9

 Asthenia

3

4.9

 Intestinal obstruction

4

6.6

 Elevated aminotransferase

1

1.6

 Allergic reaction

1

1.6

 Rash

6

9.8